Study of AZD0486 alone or with other drugs for B-cell cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called AZD0486, alone or with other medicines, for people with certain types of B-cell cancers that have come back or not responded to treatment. The goal is to see how safe and effective it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of B-cell cancer, such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), or large B-cell lymphoma (LBCL).
- You should be able to take care of yourself and do daily activities (ECOG score 0 to 2).
- You need to use birth control during treatment and for at least 90 days after the last dose.
- Your cancer must have progressed after at least 1 or 2 prior treatments, depending on the subtype you have.
- You cannot have cancer that has spread to the brain or spinal cord, or certain heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AZD4512, alone or with other cancer treatments, for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior therapies. It aims to find out if AZD4512 can help when standard options are limited.
This trial tests a combination of three drugs (sonrotoclax, rituximab, and zanubrutinib) for people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or mantle cell lymphoma. The goal is to see if the combination works better than current treatments.
This trial tests a new drug, surovatamig, for people with certain types of non-Hodgkin lymphoma that have come back or not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors and help patients.
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
This trial tests a new investigational drug (AZD0486) given alone to see if it is safe and effective for people with B-cell acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to treatment. It specifically targets a protein called CD19 found on leukemia cells.
This trial tests a new drug called AZD3470, given alone or with other cancer treatments, for people with certain types of lymphoma (Hodgkin's lymphoma or T-cell lymphoma). It aims to see if the drug is safe and effective for patients who have already tried other treatments.
Hear when a new Small Lymphocytic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.